Tonix Pharmaceuticals Presents Strong Post-Hoc Phase 3 Data for FDA-Approved Fibromyalgia Drug TONMYA™
TNXP is trading near its 52-week low of $12.35 (13% above the low).
Summary
Tonix Pharmaceuticals announced positive post-hoc Phase 3 data presentations for its FDA-approved fibromyalgia drug, TONMYA™, highlighting rapid pain relief and a favorable benefit-risk profile.
Key Events · Product Development and Regulatory · TNXP
-
Rapid Pain Relief Demonstrated
Post-hoc analysis of the RESILIENT Phase 3 trial showed TONMYA™ provided rapid pain reduction in fibromyalgia patients, with improvements observed as early as Day 2 and statistically significant relief over 14 weeks.
-
Favorable Benefit-Risk Profile
A pooled analysis of Phase 3 trials (RELIEF and RESILIENT) indicated a Likelihood to be Helped or Harmed (LHH) of 3.7, suggesting a nearly four-fold greater likelihood of clinical benefit than adverse event-related discontinuation.
-
Reinforces Commercial Potential
These presentations provide strong supporting data for TONMYA™, an FDA-approved drug launched in November 2025, which is the first new treatment for fibromyalgia in over 15 years.
Analysis · TNXP · Life Sciences
This filing details positive post-hoc analyses of Phase 3 data for TONMYA™, an FDA-approved drug for fibromyalgia that was launched in November 2025. The data reinforces TONMYA's efficacy, showing rapid pain relief as early as Day 2 and a favorable benefit-risk profile. This information strengthens the commercial narrative for TONMYA, potentially boosting physician adoption and market penetration for a product positioned as the first new fibromyalgia treatment in over 15 years. Investors should view this as positive validation for a key revenue driver.
At the time of this filing, TNXP was trading at $13.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.3M. The 52-week trading range was $12.35 to $69.97. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.